CML practitioners need dependable, well researched information to help make the best decisions for their CML patients. International therapeutic guidelines on the management of CML based on the latest research and written by leading CML experts provide a reliable and independent source of information.
This section provides access to a selection of relevant international CML guidelines designed to assist you in the management of your CML patients. These guidelines include:
If you have additional information to provide, please contact us at email@example.com.
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009.
Chronic Myelogenous Leukemia
National Comprehensive Cancer Network
Once registered you will get a copy of the guidelines for your personal use only.
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
A working group of CML patients from the CML Advocates Network, advised by medical experts, has developed a summary of the 2013 ELN recommendations in a patient-friendly language. This summary aims to help CML patients to discuss disease management and treatment choices with their doctors.
The patient-friendly summary is currently available in 17 different languages including Arabic, Bulgarian, Chinese, Danish, Dutch, English, French, German, Hebrew, Italian, Polish, Portuguese, Russian, Serbian, Spanish and Turkish.
Managing children with chronic myeloid leukaemia (CML)
Recommendations for the management of CML in children and young people up to the age of 18 years
De la Fuente J et al. Br J of Haematol 2014;167:33-47.
Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that in adults.